Also found in: Medical, Wikipedia.


a. poliarticular, que afecta varias articulaciones.
References in periodicals archive ?
A biologic drug, Enbrel is indicated for the treatment of several chronic conditions, including moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and moderate-to-severe plaque psoriasis.
It is indicated for moderate to severe plaque psoriasis and active psoriatic arthritis, as well as moderate to severe active rheumatoid arthritis, active ankylosing spondylitis, Crohn's disease, ulcer ative colitis, and polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.
The CHMP also recommends approval of the product for the treatment of paediatric inflammatory diseases, including moderate to severe Crohn's disease (age six and older), severe chronic plaque psoriasis (age four and older), enthesitis-related arthritis (age six and older) and polyarticular juvenile idiopathic arthritis (age two and older).
The company said Xatmep is indicated for the treatment of acute lymphoblastic leukemia (ALL) and the management of polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients.
7) A primary metabolic disorder or familial predisposition should be considered if CC occurs in patients <55 years, or if there is florid polyarticular CC.
An important pattern is the idea of polyarticular versus monoarticular disease.
In addition, data from recently completed abatacept Phase 3 trials in psoriatic arthritis (PsA) and polyarticular juvenile idiopathic arthritis (pJIA) will be presented.
He had a prosthetic right hip and history of chronic polyarticular pain.
A 27-year-old male was seen for a two-month history of fever, lethargy, polyarticular arthralgias, and eruptions over the palms and the soles.
Global Markets Direct's, 'Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2016', provides an overview of the Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline landscape.
HUMIRA is a fully human anti-TNF-alpha monoclonal antibody which is approved for the following indications in Japan: "treatment of rheumatoid arthritis (including prevention of structural joint damage) and the following diseases that do not sufficiently respond to existing treatments: psoriasis vulgaris; arthropathic psoriasis; ankylosing spondylitis; polyarticular juvenile idiopathic arthritis; intestinal Behcet's disease; moderate to severe active Crohn's disease as remission induction and maintenance therapy; and moderate to severe ulcerative colitis.